RxDoctor Payments Data

Michele Pierce, PA

Physician Assistant · Waterbury, CTNPI 1255668968

Payments from drug & device makers

$1,315in general payments, 2019–2025

Across 59 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$186
  • Madrigal Pharmaceuticals$154
  • Gilead$148
  • Takeda Pharmaceuticals U.S.A., Inc.$141
  • Phathom Pharmaceuticals, Inc.$118
  • Regeneron Healthcare Solutions, Inc.$112
  • plus $456 from 12 others

What the payments were for

  • Food & beverage$1,29899%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,315 in reported general payments places this provider in the 80th percentile of 1,795 physician assistant providers in Connecticut.

See all physician assistant providers in Connecticut

Medicare billing

Part B allowed, 2024
$53,210
Medicare patients
292
Services billed
464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab49$425,279
LinzessLinaclotide219$240,835
CreonLipase/Protease/Amylase87$177,339
SucraidSacrosidase12$167,746
XifaxanRifaximin41$156,849
MotegrityPrucalopride Succinate108$75,438
ZenpepLipase/Protease/Amylase25$61,152
Mesalamine58$47,611
Dexlansoprazole DrDexlansoprazole171$45,041
Lubiprostone201$31,303
IbsrelaTenapanor Hcl12$30,910
TrulancePlecanatide31$26,210
Mesalamine ErMesalamine45$12,856
Sucralfate85$11,349
Famotidine592$10,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$186$418,175306 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$19$183,05872 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Dexilant$141$85,208128 claims
Aimmune Therapeutics, Inc.Zenpep$14$61,15225 claims
Ardelyx, Inc.Ibsrela$80$30,91012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,795 physician assistant providers in Connecticut.

Other physician assistant in Waterbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →